Skip to main content
Premium Trial:

Request an Annual Quote

Life Technologies, DKFZ to Create High-Throughput Sequencing Center

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Life Technologies and the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) have formed an exclusive partnership to create the National High-Throughput Sequencing Center in Germany.

The partners said in a statement released after the close of the market Wednesday that the new center will be the largest sequencing facility in Germany and the first national sequencing center in Europe dedicated to systems biology.

The center will use 10 of Life Technologies' SOLiD 4 hq systems, which have been acquired by DKFZ. Researchers at the new center plan to initially sequence 1,000 whole human cancer genomes for Germany's national contribution to the International Cancer Genome Consortium.

"This center will be the first facility that will systematically bring high-throughput sequencing technologically into systems biology applications on a large scale," Life Technologies President and COO Mark Stevenson said in a statement.

The facility will be partly funded by the German Federal Ministry of Education and Research. Further financial and other terms of the collaboration were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.